Patents by Inventor Nikolai A. Kley

Nikolai A. Kley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FIBROBLAST BINDING AGENTS AND USE THEREOF
    Publication number: 20240148824
    Abstract: The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: January 2, 2024
    Publication date: May 9, 2024
    Inventors: Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS
  • Fibroblast binding agents and use thereof
    Patent number: 11896643
    Abstract: The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: February 13, 2024
    Assignee: Orionis Biosciences, Inc.
    Inventors: Nikolai Kley, Jan Tavernier, Anje Cauwels
  • THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES
    Publication number: 20240025980
    Abstract: The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
    Type: Application
    Filed: July 20, 2023
    Publication date: January 25, 2024
    Inventors: Nikolai KLEY, Jan TAVERNIER, Leander HUYGHE, Anje CAUWELS
  • TARGETED THERAPEUTIC AGENTS AND USES THEREOF
    Publication number: 20230399406
    Abstract: The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.
    Type: Application
    Filed: April 18, 2023
    Publication date: December 14, 2023
    Inventors: Jan TAVERNIER, Nikolai KLEY
  • PD-1 AND PD-L1 BINDING AGENTS
    Publication number: 20230295304
    Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: October 5, 2022
    Publication date: September 21, 2023
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • IMMUNOSTIMULATORY ADJUVANTS
    Publication number: 20230293652
    Abstract: The present invention relates, in part, to vaccine compositions, adjuvants, chimeric proteins, or chimeric protein complexes and their use as vaccines or therapeutic agents. The present invention further relates to methods of vaccination or treatment of various diseases.
    Type: Application
    Filed: July 7, 2021
    Publication date: September 21, 2023
    Inventors: Nikolai KLEY, Jan TAVERNIER, Frank PEELMAN, Sarah GERLO, Bram VAN DEN EECKHOUT
  • BI-FUNCTIONAL CHIMERIC PROTEINS AND USES THEREOF
    Publication number: 20230287131
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by mutant forms of soluble agents that are part of the chimeric proteins. Pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Application
    Filed: May 30, 2023
    Publication date: September 14, 2023
    Inventors: Nikolai KLEY, Jan TAVERNIER, Leander HUYGHE, Thomas WUEEST
  • Therapeutic targeting of non-cellular structures
    Patent number: 11753463
    Abstract: The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: September 12, 2023
    Assignee: Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Leander Huyghe, Anje Cauwels
  • Bi-functional chimeric proteins and uses thereof
    Patent number: 11702477
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by mutant forms of soluble agents that are part of the chimeric proteins. Pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: July 18, 2023
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Leander Huyghe, Thomas Wueest
  • Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
    Patent number: 11661455
    Abstract: The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: May 30, 2023
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Nikolai Kley
  • CD8 BINDING AGENTS
    Publication number: 20230142099
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Application
    Filed: December 1, 2022
    Publication date: May 11, 2023
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION
    Publication number: 20230111853
    Abstract: The invention provides cereblon binders for the degradation of proteins by the ubiquitin proteasome pathway for therapeutic applications.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 13, 2023
    Inventors: Nikolai KLEY, Riccardo SABATINI, Edward SUH
  • DETECTION OF NOVEL DEGRADATION-RELATED INTERACTIONS
    Publication number: 20230116707
    Abstract: The present invention is related to a method for detecting and identifying protein-protein or protein-small molecule interactions using a bait and prey system. It is also related to bait and prey proteins, small molecules and constructs that are used for the methods described herein.
    Type: Application
    Filed: December 17, 2020
    Publication date: April 13, 2023
    Inventors: Nikolai KLEY, Samuel LIEVENS
  • THERAPEUTIC INTERFERON ALPHA 1 PROTEINS
    Publication number: 20230103946
    Abstract: The present invention relates, in part, to chimeric proteins or chimeric protein complexes, such as Fc-based chimeric protein complexes, comprising interferon alpha 1, or a variant thereof, and their use as therapeutic agents.
    Type: Application
    Filed: July 21, 2022
    Publication date: April 6, 2023
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION
    Publication number: 20230099031
    Abstract: The disclosure relates to new compounds, including bifunctional compounds, to be used as modulators of ubiquitination for targeted protein degradation.
    Type: Application
    Filed: December 16, 2020
    Publication date: March 30, 2023
    Inventors: Nikolai KLEY, Riccardo SABATINI, Edward SUH
  • CD8 binding agents
    Patent number: 11566072
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: January 31, 2023
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Lennart Zabeau, Erik Depla
  • DETECTION OF MOLECULAR INTERACTIONS
    Publication number: 20230026360
    Abstract: Methods for detection of molecular interactions, such as protein/protein or small molecule/protein interactions, are described.
    Type: Application
    Filed: December 15, 2020
    Publication date: January 26, 2023
    Inventors: Nikolai KLEY, Samuel LIEVENS, Edward SUH
  • MODULATION OF PROTEIN DEGRADATION
    Publication number: 20230020607
    Abstract: Methods of assessing the efficacy of an agent in treating a disease or disorder are provided that include determining whether the agent causes, or inhibits, direct or indirect recruitment and/or ubiquitination and/or degradation of argininosuccinate synthetase 1 (ASS1).
    Type: Application
    Filed: December 15, 2020
    Publication date: January 19, 2023
    Inventors: Nikolai KLEY, Samuel LIEVENS, Riccardo SABATINI
  • PD-L1 TARGETED CHIMERIC PROTEINS AND USES THEREOF
    Publication number: 20230002493
    Abstract: The present invention relates, in part, to agents that bind PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-L1 targeting moiety and their use in the treatment of various diseases.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 5, 2023
    Inventors: Nikolai KLEY, Erik DEPLA
  • CONJUGATED CHIMERIC PROTEINS
    Publication number: 20220378925
    Abstract: The present invention relates, in part, to pegylated chimeric proteins comprising one or more targeting moieties, linkers, and one or more signaling moieties, or variants thereof, and their use as therapeutic agents.
    Type: Application
    Filed: September 25, 2020
    Publication date: December 1, 2022
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU